SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-19-135814
Filing Date
2019-05-03
Accepted
2019-05-03 07:43:34
Documents
4
Period of Report
2019-05-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d693412d8k.htm 8-K 28374
2 EX-10.1 d693412dex101.htm EX-10.1 759806
3 EX-10.2 d693412dex102.htm EX-10.2 215786
4 EX-99.1 d693412dex991.htm EX-99.1 13505
  Complete submission text file 0001193125-19-135814.txt   1018828
Mailing Address 7020 KIT CREEK ROAD SUITE 270 RESEARCH TRIANGLE PARK NC 27709
Business Address 7020 KIT CREEK ROAD SUITE 270 RESEARCH TRIANGLE PARK NC 27709 919-313-9650
AERIE PHARMACEUTICALS INC (Filer) CIK: 0001337553 (see all company filings)

IRS No.: 203109565 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36152 | Film No.: 19794050
SIC: 2836 Biological Products, (No Diagnostic Substances)